Skip to content

Newsroom

type
year
Illustration image.png

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

6/18/2026 Flagging notifications
Illustration image.png

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

6/17/2026 Flagging notifications
Illustration image.png

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

6/16/2026 Flagging notifications
Illustration image.png

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

6/15/2026 Flagging notifications
Orion Pharma_Veturi_100K Cancers_1500x844.jpg

The Veturi research ecosystem led by Orion: Personalised medicine is now advancing rapidly

6/15/2026 Science and Partnering
Illustration image.png

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

6/11/2026 Flagging notifications
Illustration image.png

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

6/10/2026 Flagging notifications
Illustration image.png

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

6/5/2026 Flagging notifications
Illustration image.png

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

6/1/2026 Flagging notifications
Illustration image.png

Orion Pharma announces first results from Phase 1/2 TEADES trial with TEAD inhibitor ODM-212 in patients with advanced solid tumours

5/30/2026 Press release
Illustration image.png

Orion Pharma to present its first clinical data from Phase 1/2 TEADES trial of TEAD inhibitor ODM-212 at the 2026 ASCO® Annual Meeting

5/21/2026 Press release
Illustration image.png

105,950 Orion Corporation A shares converted into B shares

5/15/2026 Stock exchange release
Illustration image.png

Orion Animal Health receives US FDA approval for Tessie® (tasipimidine oral solution) for the treatment of noise aversion and separation anxiety in dogs

5/12/2026 Press release
CMI_1.jpg

A stable society does not appear out of the blue – Orion and CMI open discussions about lasting peace in an evolving world

5/11/2026
Illustration image.png

Orion Corporation: Managers’ transactions – Karen Lykke Sørensen

5/4/2026 Managers transactions
Illustration image.png

Orion Corporation: Managers’ transactions – Henrik Stenqvist

5/4/2026 Managers transactions
Illustration image.png

Orion Corporation: Managers’ transactions – Hilpi Rautelin

5/4/2026 Managers transactions
Illustration image.png

Orion Corporation: Managers’ transactions – Veli-Matti Mattila

5/4/2026 Managers transactions